Although it can be determined that glycolysis does contribute to NLRP3 inflammasome activation, the idea of regulating inflammasomes by glycolysis has been experimentally demonstrated in the treatment of many inflammatory diseases, such as atherosclerosis, obesity, diabetes, tuberculosis and Rheumatoid arthritis. Here, NLRP3 is linked to obesity due to melanocortin 4 receptor deficiency.